Prescriber Checkup | OPDIVO

Prescriber Checkup

The Doctors and Drugs in Medicare Part D

Prescriber Checkup » OPDIVO

OPDIVO

NIVOLUMAB

At a Glance: This Drug in 2016

2,968
Medicare Part D Claims

Rank: 1761 of 3393

$26.2M
Retail Cost

Rank: 662 of 3393

544
Patients

Rank: 1925 of 3393

299
Prescribers

Rank: 2139 of 3393

This Drug's History

Claims

The number of Medicare prescriptions for this drug each year

N/A

2012

N/A

2013

N/A

2014

1,215

2015

2,968

2016

Spending

The total Part D spending on this drug
each year

N/A

2012

N/A

2013

N/A

2014

$11.1M

2015

$26.2M

2016

Average Patient Cost

Average amount that patients paid each year.

N/A

2012

N/A

2013

N/A

2014

$35.1K

2015

$48.2K

2016

Use by state

State Patients Claims Cost
New York 141 652 $6.3M
California 101 557 $4.98M
Florida 65 333 $2.85M
New Jersey 49 271 $2.52M
Texas 22 158 $1.04M
Illinois 21 131 $1.13M
Tennessee 24 124 $1.19M
Maryland 23 106 $1.09M
Mississippi 11 94 $745K
Massachusetts 14 87 $643K
Louisiana 11 86 $531K
Indiana 63 $553K
Connecticut 55 $477K
Georgia 53 $536K
North Carolina 46 $424K
Michigan 27 $266K
Vermont 20 $108K
Pennsylvania 17 $68.9K
Kentucky 17 $195K
Colorado 13 $127K
Virginia 13 $101K
Hawaii 13 $52.1K
About This Data

Prescribing data from Medicare’s prescription drug benefit, known as Part D, was compiled and released by the Centers for Medicare and Medicaid Services, the federal agency that oversees the program. The data for 2016 includes more than 1.5 billion prescriptions written by 1.1 million doctors, nurses and other providers. This database lists over 460,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. More than three-fourths of these prescriptions went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to [email protected] and we will update your information. If you have other questions about this data, send a note to [email protected].